Previous 10 | Next 10 |
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upco...
ImmunoGen, Inc. (IMGN) Q4 2020 Earnings Conference Call February 12, 2021 08:00 ET Company Participants Courtney O’Konek - Senior Director, Corporate Communications and Investor Relations Mark Enyedy - President and Chief Executive Officer Anna Berkenblit - Chief Medical Officer Susan ...
Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...
Gainers: Artelo Biosciences (ARTL) +82%.Wunong Net Technology Company (WNW) +72%.China Liberal Education Holdings (CLEU) +53%.ION Geophysical (IO) +42%.Top Ships (TOPS) +42%.Seanergy Maritime Holdings (SHIP) +34%.Luokung Technology (LKCO) +29%.ImmunoGen (IMGN) +29%.EuroDry (EDRY) +28%.Lizhi (...
Image source: The Motley Fool. Immunogen Inc (NASDAQ: IMGN) Q4 2020 Earnings Call Feb 12, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Immunogen Inc (IMGN) Q4 2020 Earnings Call Transcript
If you liked the gains generated by ImmunoGen (NASDAQ: IMGN) in 2020, you're loving the stock in 2021. So far this year, the biotech's shares have soared 32%. And that momentum is now likely to build even more. ImmunoGen announced its fourth-quarter results before the market ope...
ImmunoGen (IMGN) Q4 results:Revenues: $85.8M (+91.3%), beats by $44.97M; non-cash royalty revenue: $23.4M, compared with $15.3M last year, helped by rising global sales of breast cancer treatment Kadcyla; Research and development expenses were $39.6M vs $26.1M.Net inc...
ImmunoGen (IMGN): Q4 GAAP EPS of $0.16 beats by $0.24.Revenue of $85.8M (+91.3% Y/Y) beats by $44.97M.For 2021, ImmunoGen expects: Revenues between $65M and $75M; operating expenses between $200M and $210M; and cash and cash equivalents at December 31, 2021 to be between $140M and $150M....
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Fund...
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upco...
News, Short Squeeze, Breakout and More Instantly...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...
2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...